Real-World Strategies to Support Oncology Teams Who Care for Women with Recurrent Ovarian Cancer

Real-World Strategies to Support Oncology Teams Who Care for Women with Recurrent Ovarian Cancer is organized by Prime Education, LLC.

Release Date: January 31, 2020
Expire Date: January 31, 2021

Accreditation:
Interprofessional Teams:
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credits for learning and change.

Physician Credit Designation Statement:
PRIME® designates this Enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Accreditation Statement:
This activity is approved for 1.0 contact hour of continuing education (which includes 0.36 hour of pharmacology) by the American Association of Nurse Practitioners. 

Physician Assistant Accreditation Statement:
PRIME® has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Nurse Accreditation Statement:
PRIME® designates this activity for 1.0 contact hour.

Case Manager Accreditation Statement:
The Commission for Case Manager Certification designates this educational activity for 1.0 contact hour for certified case managers. 

Overview:
In this webcast, leading ovarian cancer experts share aggregated findings garnered during a quality improvement initiative conducted at two large oncology health systems.

Discussion focuses on:
• Real-world insights into the challenges of integrating PARP inhibitors for patients with recurrent ovarian cancer
• Strategies to integrate best practices for evidence-based and guideline-compliant care
• Patient-centered approaches to treatment decision-making and monitoring

Learning Objectives:
• Identify distinguishing characteristics among FDA-approved PARP inhibitors
• Evaluate challenges in evidence-based integration of PARP inhibitors
• Assess pivotal clinical trial evidence on the efficacy and safety of PARP inhibitors
• Apply evidence-based guidelines for maintenance treatment decision-making in the recurrent ovarian cancer setting
• Facilitate team-based strategies to improve outcomes for patients with recurrent ovarian cancer